<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Live Cell-Based Flow Cytometry Assay Versus Commercial Cell-Based Indirect Immunofluorescence Assay of Aquaporin-4 Antibody in Neuromyelitis Optica: A Comparative study

dc.contributor.authorDogan, Ipek Gungor
dc.contributor.authorYigit, Mesut
dc.contributor.authorTezer, Damla Cetinkaya
dc.contributor.authorGulacti, Ozlem
dc.contributor.authorAyhan, Sevval
dc.contributor.authorTurkdemir, Ipek Duygu
dc.contributor.authorCelik, Betul
dc.contributor.authorTasdelen, Beril
dc.contributor.authorUzunkopru, Cihat
dc.contributor.authorYetkin, Mehmet Fatih
dc.contributor.authorTutuncu, Melih
dc.contributor.authorKilercik, Meltem
dc.contributor.authorDemir, Serkan
dc.date.accessioned2026-11-05T11:01:36Z
dc.date.issued2025
dc.description.abstractIntroduction: Neuromyelitis Optica (NMO) is an inflammatory disorder affecting the central nervous system, notably the optic nerve and spinal cord. Seropositive NMO is marked by serum IgG antibodies against aquaporin-4 (AQP4). The accurate identification of AQP4-IgG is crucial for distinguishing NMO from other demyelinating diseases of the central nervous system. However, traditional diagnostic assays have limitations in sensitivity and specificity. Here, we introduce our in-house flow cytometry live cell-based assay (FC-LCBA) for detecting AQP4 antibodies with enhanced sensitivity and specificity. Our objective is to report the accuracy and compare the efficacy of our newly developed in-house FC-LCBA against the commercial cell-based indirect immunofluorescence assay (IIFA) in detecting AQP4 antibodies. Methods: This single-blind study was approved by the ethical committee and involved 101 serum samples. Twenty-five samples (including retests) from 17 patients evaluated in the NMO spectrum who had at least one positive cell-based IIFA test during the diagnosis or follow-up are tested in parallel with our in-house FC-LCBA and cell-based IIFA. In addition, 36 serum samples from myelin oligodendrocyte glycoprotein-associated disease (MOGAD) patients and 40 serum samples from healthy subjects are also referred for specificity analysis. Results: Our in-house FC-LCBA displayed superior sensitivity, detecting positive results even when the cell-based IIFA yielded negative results in patients under immunosuppressive treatments. Additionally, FC-LCBA exhibited high specificity for NMO, showing negligible antibody levels in patients with MOGAD diagnosis and healthy individuals. The assay's stability was confirmed through consistent results in retests. Conclusion: Our in-house FC-LCBA emerges as a promising diagnostic tool for detecting AQP4 antibodies, offering improved sensitivity, specificity, and reliability, instilling confidence in its potential.
dc.description.issue3
dc.description.pages259-263
dc.description.sponsorshipThis study was fully funded by SZA Health Research and Development Corporation.
dc.description.volume62
dc.identifier.doi10.29399/npa.28951
dc.identifier.issn1300-0667
dc.identifier.issn1309-4866
dc.identifier.urihttps://doi.org/10.29399/npa.28951
dc.identifier.urihttps://openaccess.acibadem.edu.tr/handle/11443/10763
dc.identifier.wosWOS:001666725000010
dc.language.isoen
dc.publisherTURKISH NEUROPSYCHIATRY ASSOC-TURK NOROPSIKIYATRI DERNEGI
dc.relation.fundingSZA Health Research and Development Corporation
dc.relation.hasversion10.29399/npa.28951
dc.relation.ispartofNOROPSIKIYATRI ARSIVI-ARCHIVES OF NEUROPSYCHIATRY
dc.subjectAquaporin-4 antibodies
dc.subjectflow cytometry
dc.subjectlive cell-based assay
dc.subjectneuromiyelitis optica
dc.subjectserological diagnosis
dc.subjectMARKER
dc.subjectNMO
dc.subjectPATHOGENESIS
dc.subjectSEROSTATUS
dc.subjectIGG
dc.subjectClinical Neurology
dc.subjectNeurosciences & Neurology
dc.titleLive Cell-Based Flow Cytometry Assay Versus Commercial Cell-Based Indirect Immunofluorescence Assay of Aquaporin-4 Antibody in Neuromyelitis Optica: A Comparative study
dc.typeArticle
oaire.citation.editionScience Citation Index Expanded (SCI-EXPANDED)
oaire.citation.endPage263
oaire.citation.issue3
oaire.citation.startPage259
oaire.citation.volume62
person.identifier.ridJAC-4300-2023
person.identifier.ridW-4303-2017
person.identifier.ridAAS-5296-2020
person.identifier.ridAAF-1702-2021
person.identifier.ridA-2173-2016

Files

Collections